-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
ACH-806
![{PARAM:[Name]}({[CAS]})](https://resource.bocsci.com/structure/870142-71-5.gif)
| Category | Hepatitis C Virus (HCV) |
| CAS | 870142-71-5 |
| Description | ACH-806 is a Hepatitis C virus NS3 protein inhibitor. It can inhibit viral RNA replication in HCV replicon cells and is active in genotype 1 HCV-infected patients in a proof-of-concept clinical trial. But Phase-II for Hepatitis C treatment was discontinued. |
Product Information
| Synonyms | ACH-806; ACH 806; ACH806; GS-9132; GS9132; GS 9132; N-(((4-(pentyloxy)-3-(trifluoromethyl)phenyl)amino)thioxomethyl)-3-Pyridinecarboxamide, |
| IUPAC Name | N-[[4-pentoxy-3-(trifluoromethyl)phenyl]carbamothioyl]pyridine-3-carboxamide |
| Molecular Weight | 411.45 |
| Molecular Formula | C19H20F3N3O2S |
| Canonical SMILES | CCCCCOc1ccc(cc1C(F)(F)F)NC(=S)NC(=O)c2cccnc2 |
| InChI | 1S/C19H20F3N3O2S/c1-2-3-4-10-27-16-8-7-14(11-15(16)19(20,21)22)24-18(28)25-17(26)13-6-5-9-23-12-13/h5-9,11-12H,2-4,10H2,1H3,(H2,24,25,26,28) |
| InChIKey | WJSGOXONRXFGRY-UHFFFAOYSA-N |
| Purity | 98% |
| Solubility | Soluble in DMSO |
| Appearance | Powder |
| Application | HCV |
| Shelf Life | 2 month in rt, long time |
| Storage | -20°C Freezer |
| Complexity | 519 |
| Exact Mass | 411.12300 |
| In Vitro | ACH-806 is an NS4A antagonist that inhibits hepatitis C virus (HCV) replication at 14 nM for EC50. ACH-806 treatment results in a significant reduction in NS3 and NS4A in transfected cells. |
| PSA | 105.87000 |
| Target | HCV Protease; HCV |
| XLogP3-AA | 5.1 |